Om os

Scandion Oncology A/S has a unique mission: to develop drugs that specifically target drug resistance mechanisms with the aim to extend survival of cancer patients and at the same time improve quality of life of these patients.The business idea is that Scandion Oncology A/S will develop SCO-101 and SCO-201 as add- on medication to treat chemotherapy resistant cancer. SCO-101 is ready for phase II trial and SCO-201 is in preclinical development. After having succesfully completed a Proof of Concept phase II study, Scandion Oncology will outlicense to or seek partnership with big pharma in order to bring the drugs to registration and thereby commercialization.